Penny stocks often offer tremendous upside for investors. As a result, they also expose investors to significant risk as well. One of the highest risk-to-reward subsectors of penny stocks is biotech. It offers dozens of get-rich-quick opportunities that are ultimately all predicated on FDA approval. Most fail. This list includes zero biotech firms, but also offers double-your-money potential across various other high-growth sectors.
These penny stocks have the potential for impressive double-up returns, while also providing stable business models and consistent outlooks.
This post appeared first on InvestorPlace.